)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Caribou Biosciences
Caribou Biosciences (CRBU) investor relations material
Caribou Biosciences Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary5 Nov, 2026
Executive summary
Oct. 6 Board-approved restructuring includes a strategic alternatives review, planned discontinuation of vispa-cel and CB-011, a substantial workforce reduction and other cost cuts.
Alternatives may include a merger, acquisition, business combination, dissolution or liquidation; no timeline or transaction is assured.
A transaction committee was formed and Wedbush Securities engaged as exclusive financial advisor.
Financial highlights
Q3 revenue was $1.6M vs. $2.2M YoY; 9M revenue was $5.5M vs. $7.2M.
Q3 operating loss was $27.6M vs. $29.4M and net loss was $26.6M vs. $27.5M; 9M operating loss was $79.3M vs. $119.9M and net loss was $76.0M vs. $121.6M.
Q3 R&D expense was $21.3M vs. $22.4M; 9M R&D expense was $60.9M vs. $85.6M. Q3 G&A was $7.9M vs. $9.2M; 9M G&A was $23.9M vs. $29.3M.
Basic and diluted loss per share was $0.25 in Q3 vs. $0.30 YoY and $0.75 for 9M vs. $1.31.
Outlook and guidance
Cash, cash equivalents and marketable securities of $94.8M at Sept. 30 are expected to fund the current operating plan for at least 12 months from the filing date.
Estimated 2026 restructuring costs are $15M-$19M, including $10M-$11M for severance and related costs and $5M-$8M to wind down two trials; a substantial portion is expected in Q4.
Additional costs may arise from lease actions, contract and license terminations, or long-lived asset impairments; amounts are not yet estimated.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Caribou Biosciences
- Net loss narrowed to $24.3M in Q2 2026, with $113.8M in cash supporting ongoing CAR-T trials.CRBU
Q2 2026 - Key CAR-T programs advance toward pivotal trials, with data and regulatory updates due this year.CRBUJefferies Global Healthcare Conference 2025
- Off-the-shelf CAR-T pipeline advances with pivotal trials and autoimmune expansion, backed by strong cash reserves.CRBU7th Annual Evercore ISI HealthCONx Conference
- Vispa-cel and CB-011 advance off-the-shelf CAR T therapy with strong efficacy, safety, and access.CRBUH.C. Wainwright 4th Annual Cell Therapy Virtual Conference
- Director elections and auditor ratification passed; officer exculpation amendment failed.CRBUAGM 2026
- CB-011 achieved high response rates and durable remissions with manageable safety in r/r myeloma.CRBUCorporate presentation
- Key votes include director elections, auditor ratification, and officer exculpation amendment.CRBUProxy filing
- Pivotal-ready and phase I CAR T programs advance, with major data updates expected at EHA.CRBUJefferies Global Healthcare Conference 2026
- Upcoming data on allogeneic cell therapies signal progress toward scalable, curative autoimmune treatments.CRBUCiti's 2024 Global Healthcare Conference
Next Caribou Biosciences earnings date
Q4 20269 Mar, 2027
Caribou Biosciences
Next Caribou Biosciences earnings date
Q4 20269 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Caribou Biosciences Inc. is a clinical-stage biopharmaceutical company at the forefront of genome editing technology. It focuses on developing genome-edited allogeneic cell therapies for the treatment of cancer and other devastating diseases. The company utilizes CRISPR-Cas9 technology to create precise, directed changes in the DNA of living cells, aiming to develop innovative therapies that can address unmet medical needs. Caribou's leading product candidates include allogeneic chimeric antigen receptor T (CAR-T) cell therapies for hematologic malignancies and solid tumors. This approach allows for the development of therapies that are not patient-specific but can be used as "off-the-shelf" treatments, potentially reducing time and cost compared to traditional autologous CAR-T therapies. The company is headquartered in Berkeley, CA, and its shares are listed on the NASDAQ.